DOI:10.1111/j.1365-2125.2005.02460.x

AUTHOR INDEX

AARONS, L. *see* HUSSEIN, Z.
AARTS, L.P.H.J. *see* KNIBBE, C.A.J.
AGÚNDEZ, J.A.G. *see* MARTÍNEZ, C.
AKOVA, Y.A. *see* ALTAN-YAYCIOGLU, R.
AL-ADHI, B. *see* AL-MOTARREB, A.
AL-AMOUD, A.I., CLARK, B.J., ASSI, K.A. & CHRYSTYN, H. Determination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers: 542
ALEMAO, E. *see* VAN GANSE, E.
AL-JABER, N. *see* AL-MOTARREB, A.
AL-JAILANI, F. *see* AL-MOTARREB, A.
ALLEGAERT, K., COSSEY, V., DEBEER, A., DEVLIEGER, H., VAN OVERMEIRE, B. & DE HOON, J. The impact of ibuprofen administration on amikacin clearance in preterm infants is independent of the gestational age: 609
AL-MOTARREB, A., BRIANCON, S., AL-JABER, N., AL-ADHI, B., AL-JAILANI, F., SALEK, M.S. & BROADLEY, K.J. Khat chewing is a risk factor for acute myocardial infarction: a case-control study: 574
ALTAN-YAYCIOGLU, R., YAYCIOGLU, O., AKOVA, Y.A., GUVEL, S. & OZKARDES, H. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial: 588
AMICO, J.A. *see* HRUSKA, M.W.
AMMIT, A.J. *see* JIANG, X.M.
ARAKAWA, M., OHMORI, M., HARADA, K.-I., ARAKI, N., SAITOH, T. & FUJIMURA, A. Different accumulation of temocapril and enalapril during repeated dosing in elderly patients: 489
ARAKI, N. *see* ARAKAWA, M.
ARONSON, J.K. Biomarkers and surrogate endpoints: 491
ARONSON, J.K. Drug development: more science, more education: 377
ARONSON, J.K. Internationality: 1
ARONSON, J.K. Moving about: 263
ARONSON, J.K. *see* FERNER, R.E.
ARONSON, J.K. Write on: 141
ASGHAR, A. *see* PINTO, A.G.
ASHTON, M. *see* GORDI, T.
ASSI, K.A. *see* AL-AMOUD, A.I.
ASTRUC, B., TARRAL, A., DOSTERT, P., MARIOTTI, F., FABBRI, L. & IMBIMBO, B.P. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects: 405
ATARASHI, S. *see* PAYNE, G.S.
ATCHESON, B.A., TAYLOR, P.J., MUDGE, D.W., JOHNSON, D.W., HAWLEY, C.M., CAMPBELL, S.B., ISBEL, N.M., PILLANS, P.I. & TETT, S.E. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant: 271
ATHERTON, J. *see* GREEN, B.
AUMORA, B. *see* HOMBHANJE, F.W.
AUTRET-LECA, E. *see* BOURGOIN, H.

BABER, N. *see* PRITCHARD, D.S.
BABER, N.S. & SMYTH, R. Introduction to Tripartite Meeting Report (convenors: Dr Nigel Baber and Prof. Ros Smyth): Towards establishing optimal doses for drugs prescribed to children: 655
BABER, N.S. Paediatric special edition: 651
BABER, N.S. Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?: 660
BACK, D. *see* BOFFITO, M.
BACKMAN, J.T. *see* LILJA, J.J.
BAL DIT SOLLIER, C. *see* MAHÉ, I.
BAND, M. *see* DAVIES, J.
BARNETT, D.B. *see* STANLEY, A.G.
BAS, M., HOFFMANN, T.K., BIER, H. & KOJDA, G. Increased C-reactive protein in ACE-inhibitor-induced angioedema: 233
BEGGS, S. *see* TITCHEN, T.
BEIJNEN, J.H. *see* BOSCH, T.M.
BEIJNEN, J.H. *see* DE JONGE, M.E.
BEIJNEN, J.H. *see* KAPPELHOFF, B.S.
BENEZRA, D. *In vitro* fertilization and childhood retinoblastoma: 724
BENNETT, K. *see* TEELING, M.
BENNEWITH, O. *see* HAWTON, K.
BENOWITZ, N.L. *see* CSAJKA, C.
BENTZEN, N. *see* STEINSBEKK, A.
BERBICHE, D. *see* PERREAULT, S.
BERGMANN, J.F. *see* MAHÉ, I.
BERGMANN, J.-F. *see* MAHÉ, I.
BERTRAND, M. *see* VAN GANSE, E.
BERTRAND, N. *see* MAHÉ, I.
BIER, H. *see* BAS, M.
BJÖRKMAN, S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs: 691
BLAIS, L. *see* PERREAULT, S.
BLANCO, G. *see* MARTÍNEZ, C.
BOFFITO, M., BACK, D., STAINSBY-TRON, M., HILL, A., PERRI, G.D., MOYLE, G., NELSON, M., TOMKINS, J., GAZZARD, B. & POZNIAK, A. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects: 38
BOND, C. *see* STEWART, D.
BORRILL, Z.L., HOUGHTON, C.M., WOODCOCK, A.A., VESTBO, J. & SINGH, D. Measuring bronchodilation in COPD clinical trials: 379
BOSCH, T.M., KJELLBERG, L.M., MEIJERMAN, I., SMITS, P.H.M., SCHELLENS J.H.M. & BEIJNEN, J.H. Novel identified SNPs in the main ABC transporter ABCG2 (BCRP): 123
BOURBEAU, M. *see* VAN HEESWIJK, R.P.G.
BOURGOIN, H., PAINTAUD, G., BÜCHLER, M., LEBRANCHU, Y., AUTRET-LECA, E., MENTRÉ, F. & GUELLEC, C.L. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients: 18
BREDENBERG, S. *see* LENNERNÄS, B.
BRIANCON, S. *see* AL-MOTARREB, A.
BROADBENT, R. *see* LINGVALL, M.
BROADLEY, K.J. *see* AL-MOTARREB, A.
BROUWERS, J.R.B.J. *see* DE JONG, J.C.F.
BRUNE, K. *see* HINZ, B.
BÜCHLER, M. *see* BOURGOIN, H.

CAMERON, D.W. *see* VAN HEESWIJK, R.P.G.
CAMPBELL, S.B. *see* ATCHESON, B.A.
CAULIN, C. *see* MAHÉ, I.
CH STRICKER, B.H. *see* SCHELLEMAN, H.
CHA, I.-J. *see* SHON, J.-H.
CHADWICK, D. *see* OWEN, A.
CHAIKIN, P., GILLEN, M.S., MALIK, M., PENTIKIS, H., RHODES, G.R. & ROBERTS, D.J. Co-administration of ketoconazole with H_1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects: 346
CHALASANI, N. *see* PINTO, A.G.
CHAN, F.W.H. *see* YOU, J.H.S.
CHAPPUY, H. *see* JULLIEN, V.
CHEN, X.Y. *see* ZHANG, Y.F.
CHENG, G. *see* YOU, J.H.S.
CHEUNG, B.M.Y. *see* HUI, C.K.
CHEUNG, Y.-B. *see* ZHOU, Q.Y.
CHEVTS, J. *see* HINZ, B.
CHOWBAY, B. *see* ZHOU, Q.Y.
CHRYSTYN, H. *see* AL-AMOUD, A.I.
CHUI, J., TORDOFF, J. & REITH, D. Changes in availability of paediatric medicines in Australia between 1998 and 2002: 736
CLARK, B.J. *see* AL-AMOUD, A.I.

© 2005 Blackwell Publishing Ltd

DOI:10.1111/j.1365-2125.2005.02460.x

AUTHOR INDEX

AARONS, L. *see* HUSSEIN, Z.
AARTS, L.P.H.J. *see* KNIBBE, C.A.J.
AGÚNDEZ, J.A.G. *see* MARTÍNEZ, C.
AKOVA, Y.A. *see* ALTAN-YAYCIOGLU, R.
AL-ADHI, B. *see* AL-MOTARREB, A.
AL-AMOUD, A.I., CLARK, B.J., ASSI, K.A. & CHRYSTYN, H. Determination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers: 542
ALEMAO, E. *see* VAN GANSE, E.
AL-JABER, N. *see* AL-MOTARREB, A.
AL-JAILANI, F. *see* AL-MOTARREB, A.
ALLEGAERT, K., COSSEY, V., DEBEER, A., DEVLIEGER, H., VAN OVERMEIRE, B. & DE HOON, J. The impact of ibuprofen administration on amikacin clearance in preterm infants is independent of the gestational age: 609
AL-MOTARREB, A., BRIANCON, S., AL-JABER, N., AL-ADHI, B., AL-JAILANI, F., SALEK, M.S. & BROADLEY, K.J. Khat chewing is a risk factor for acute myocardial infarction: a case-control study: 574
ALTAN-YAYCIOGLU, R., YAYCIOGLU, O., AKOVA, Y.A., GUVEL, S. & OZKARDES, H. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial: 588
AMICO, J.A. *see* HRUSKA, M.W.
AMMIT, A.J. *see* JIANG, X.M.
ARAKAWA, M., OHMORI, M., HARADA, K.-I., ARAKI, N., SAITOH, T. & FUJIMURA, A. Different accumulation of temocapril and enalapril during repeated dosing in elderly patients: 489
ARAKI, N. *see* ARAKAWA, M.
ARONSON, J.K. Biomarkers and surrogate endpoints: 491
ARONSON, J.K. Drug development: more science, more education: 377
ARONSON, J.K. Internationality: 1
ARONSON, J.K. Moving about: 263
ARONSON, J.K. *see* FERNER, R.E.
ARONSON, J.K. Write on: 141
ASGHAR, A. *see* PINTO, A.G.
ASHTON, M. *see* GORDI, T.
ASSI, K.A. *see* AL-AMOUD, A.I.
ASTRUC, B., TARRAL, A., DOSTERT, P., MARIOTTI, F., FABBRI, L. & IMBIMBO, B.P. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects: 405
ATARASHI, S. *see* PAYNE, G.S.
ATCHESON, B.A., TAYLOR, P.J., MUDGE, D.W., JOHNSON, D.W., HAWLEY, C.M., CAMPBELL, S.B., ISBEL, N.M., PILLANS, P.I. & TETT, S.E. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant: 271
ATHERTON, J. *see* GREEN, B.
AUMORA, B. *see* HOMBHANJE, F.W.
AUTRET-LECA, E. *see* BOURGOIN, H.

BABER, N. *see* PRITCHARD, D.S.
BABER, N.S. & SMYTH, R. Introduction to Tripartite Meeting Report (convenors: Dr Nigel Baber and Prof. Ros Smyth): Towards establishing optimal doses for drugs prescribed to children: 655
BABER, N.S. Paediatric special edition: 651
BABER, N.S. Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?: 660
BACK, D. *see* BOFFITO, M.
BACKMAN, J.T. *see* LILJA, J.J.
BAL DIT SOLLIER, C. *see* MAHÉ, I.
BAND, M. *see* DAVIES, J.
BARNETT, D.B. *see* STANLEY, A.G.
BAS, M., HOFFMANN, T.K., BIER, H. & KOJDA, G. Increased C-reactive protein in ACE-inhibitor-induced angioedema: 233
BEGGS, S. *see* TITCHEN, T.
BEIJNEN, J.H. *see* BOSCH, T.M.
BEIJNEN, J.H. *see* DE JONGE, M.E.
BEIJNEN, J.H. *see* KAPPELHOFF, B.S.
BENEZRA, D. *In vitro* fertilization and childhood retinoblastoma: 724
BENNETT, K. *see* TEELING, M.
BENNEWITH, O. *see* HAWTON, K.
BENOWITZ, N.L. *see* CSAJKA, C.
BENTZEN, N. *see* STEINSBEKK, A.
BERBICHE, D. *see* PERREAULT, S.
BERGMANN, J.F. *see* MAHÉ, I.
BERGMANN, J.-F. *see* MAHÉ, I.
BERTRAND, M. *see* VAN GANSE, E.
BERTRAND, N. *see* MAHÉ, I.
BIER, H. *see* BAS, M.
BJÖRKMAN, S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs: 691
BLAIS, L. *see* PERREAULT, S.
BLANCO, G. *see* MARTÍNEZ, C.
BOFFITO, M., BACK, D., STAINSBY-TRON, M., HILL, A., PERRI, G.D., MOYLE, G., NELSON, M., TOMKINS, J., GAZZARD, B. & POZNIAK, A. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects: 38
BOND, C. *see* STEWART, D.
BORRILL, Z.L., HOUGHTON, C.M., WOODCOCK, A.A., VESTBO, J. & SINGH, D. Measuring bronchodilation in COPD clinical trials: 379
BOSCH, T.M., KJELLBERG, L.M., MEIJERMAN, I., SMITS, P.H.M., SCHELLENS J.H.M. & BEIJNEN, J.H. Novel identified SNPs in the main ABC transporter ABCG2 (BCRP): 123
BOURBEAU, M. *see* VAN HEESWIJK, R.P.G.
BOURGOIN, H., PAINTAUD, G., BÜCHLER, M., LEBRANCHU, Y., AUTRET-LECA, E., MENTRÉ, F. & GUELLEC, C.L. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients: 18
BREDENBERG, S. *see* LENNERNÄS, B.
BRIANCON, S. *see* AL-MOTARREB, A.
BROADBENT, R. *see* LINGVALL, M.
BROADLEY, K.J. *see* AL-MOTARREB, A.
BROUWERS, J.R.B.J. *see* DE JONG, J.C.F.
BRUNE, K. *see* HINZ, B.
BÜCHLER, M. *see* BOURGOIN, H.

CAMERON, D.W. *see* VAN HEESWIJK, R.P.G.
CAMPBELL, S.B. *see* ATCHESON, B.A.
CAULIN, C. *see* MAHÉ, I.
CH STRICKER, B.H. *see* SCHELLEMAN, H.
CHA, I.-J. *see* SHON, J.-H.
CHADWICK, D. *see* OWEN, A.
CHAIKIN, P., GILLEN, M.S., MALIK, M., PENTIKIS, H., RHODES, G.R. & ROBERTS, D.J. Co-administration of ketoconazole with H_1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects: 346
CHALASANI, N. *see* PINTO, A.G.
CHAN, F.W.H. *see* YOU, J.H.S.
CHAPPUY, H. *see* JULLIEN, V.
CHEN, X.Y. *see* ZHANG, Y.F.
CHENG, G. *see* YOU, J.H.S.
CHEUNG, B.M.Y. *see* HUI, C.K.
CHEUNG, Y.-B. *see* ZHOU, Q.Y.
CHEVTS, J. *see* HINZ, B.
CHOWBAY, B. *see* ZHOU, Q.Y.
CHRYSTYN, H. *see* AL-AMOUD, A.I.
CHUI, J., TORDOFF, J. & REITH, D. Changes in availability of paediatric medicines in Australia between 1998 and 2002: 736
CLARK, B.J. *see* AL-AMOUD, A.I.

© 2005 Blackwell Publishing Ltd

CLAUSON, P. *see* MCELDUFF, A.
COCKAYNE, N.L., DUGUID, M. & SHENFIELD, G.M. Health professionals rarely record history of complementary and alternative medicines: 254
COCKBURN, W. *see* LIPWORTH, B.J.
COHEN, A.F. *see* DUMONT, G.J.H.
COLLIN, J. *see* PERREAULT, S.
COLLINS, D.J. *see* PAYNE, G.S.
CONTI, R. *see* MAHÉ, I.
COPETTI, R., PROCLEMER, A. & PILLININI, P.P. Brugada-like ECG abnormalities during thioridazine overdose
COSSEY, V. *see* ALLEGAERT, K.
CRANSWICK, N. *see* TITCHEN, T.
CROMMENTUYN, K.M.L. *see* KAPPELHOFF, B.S.
CSAJKA, C., HALLER, C.A., BENOWITZ, N.L. & VEROTTA, D. Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects: 335
CZOCK, D., KELLER, F., HERINGA, M. & RASCHE, F.M. Raloxifene pharmacokinetics in males with normal and impaired renal function: 479

DANHOF, M. *see* KNIBBE, C.A.J.
DARTIGUES, J.-F. *see* LECHEVALLIER-MICHEL, N.
DAUKES, S.E. *see* HELMS, P.J.
DAVE, N. *see* SNELL, P.
DAVIES, J., GAVIN, A., BAND, M., MORRIS, A. & STRUTHERS, A. Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients: 520
DAY, R.O. *see* JIANG, X.M.
DE BOER, A. *see* SCHELLEMAN, H.
DE HOON, J. *see* ALLEGAERT, K.
DE HOON, J.N.J.M. *see* VANMOLKOT, F.H.M.
DE JONG, J.C.F., BROUWERS, J.R.B.J. & DE JONG-VAN DEN BERG, L.T.W. Combined use of NSAIDs and SSRIs increases the risk for gastrointestinal adverse effects: 119
DE JONGE, M.E., HUITEMA, A.D.R., SCHELLENS, J.H.M., RODENHUIS, S. & BEIJNEN, J.H. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL: 325
DE JONG-VAN DEN BERG, L.T.W. *see* DE JONG, J.C.F.
DE LA IGLESIA, F.A. *see* SMITH, M.T.
DE PONTI, F. *see* MOTOLA, D.
DE POUVOURVILLE, G. *see* VAN GANSE, E.
DE VISSER, S.J. *see* DUMONT, G.J.H.
DEBEER, A. *see* ALLEGAERT, K.
DELESEN, H. *see* STASS, H.
DEVLIEGER, H. *see* ALLEGAERT, K.
DIMET, J. *see* JULLIEN, V.
DOSTERT, P. *see* ASTRUC, B.
DRAGOMIR, A. *see* PERREAULT, S.
DRESCHER, S. *see* GLAESER, H.
DROUET, L. *see* MAHÉ, I.
DUGUID, M. *see* COCKAYNE, N.L.
DUKE, C.C. *see* JIANG, X.M.
DUMONT, G.J.H., DE VISSER, S.J., COHEN, A.F. & VAN GERVEN, J.M.A. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects: 495
DUPIN, N. *see* JULLIEN, V.
DZIK-JURASZ, A.S.K. *see* PAYNE, G.S.

EARL, J.W. *see* NATH, C.E.
EBRAHIM, S. *see* WALLER, P.
EICHELBAUM, M. *see* GLAESER, H.
EICHELBAUM, M. *see* NIEMI M.
EKINS-DAUKES, S. *see* NOVAK, P.H.
EKINS-DAUKES, S., HELMS, P.J., TAYLOR, M.W., SIMPSON, C.R. & McLAY, J.S. Paediatric homoeopathy in general practice: where, when and why?: 743
ELLIOT, R. *see* SORENSEN, L.

FØNNEBØ, V. *see* STEINSBEKK, A.
FABBRI, L. *see* ASTRUC, B.
FABRIGOULE, C. *see* LECHEVALLIER-MICHEL, N.
FEELY, J. *see* TEELING, M.
FERNER, R.E. & ARONSON, J.K. National differences in publishing papers on adverse drug reactions: 108
FERRELL, R.E. *see* HRUSKA, M.W.
FISHMAN, R. *see* LIPWORTH, B.J.
FITZGERALD, M. *see* WEEKES, L.M.
FITZGERALD, S.M. *see* HRUSKA, M.W.
FOURRIER-RÉGLAT, A. *see* LECHEVALLIER-MICHEL, N.
FROMM, M.F. *see* GLAESER, H.
FROMM, M.F. *see* NIEMI M.
FRYE, R.F. *see* HRUSKA, M.W.
FUJIMURA, A. *see* ARAKAWA, M.
FUJIMURA, A. *see* WAKAUMI, M.

GALITZ, L. *see* SNELL, P.
GAMITO, F.J.G. *see* MARTÍNEZ, C.
GARBER, G.E. *see* VAN HEESWIJK, R.P.G.
GARCÍA-MARTÍN, E. *see* MARTÍNEZ, C.
GAUDRIC, A. *see* MAHÉ, I.
GAVIN, A. *see* DAVIES, J.
GAZZARD, B. *see* BOFFITO, M.
GIBB, F.W. *see* GREIG, L.D.
GIGUERE, P. *see* VAN HEESWIJK, R.P.G.
GILLEN, M.S. *see* CHAIKIN, P.
GLAESER, H., DRESCHER, S., EICHELBAUM, M. & FROMM, M.F. Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes: 199
GLOTH, F.M. Handbook of pain relief in older adults – an evidence-based approach: 262
GÖSSL, M. *see* SAEZ, A.M.O.
GOLDRING, C. *see* OWEN, A.
GORDI, T., XIE, R., HUONG, N.V., HUONG, D.X., KARLSSON, M.O. & ASHTON, M. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction: 189
GREEN, B., GREENWOOD, M., SALTISSI, D., WESTHUYZEN, J., KLUVER, L., ROWELL, J. & ATHERTON, J. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes: 281
GREENWOOD, M. *see* GREEN, B.
GREIG, L.D., LESLIE, S.J., GIBB, F.W., TAN, S., NEWBY, D.E. & WEBB, D.J. Comparative effects of glyceryl trinitrate and amyl nitrite on pulse wave reflection and augmentation index: 265
GRIEVE, J., TORDOFF, J., REITH, D. & NORRIS, P. Effect of the Pediatric Exclusivity Provision on children's access to medicines: 730
GROENEVELD, G.J. *see* VAN KAN, H.J.M.
GROVER, A. *see* SHAFIQ, N.
GUCHELAAR, H.J. *see* VAN KAN, H.J.M.
GUELLEC, C.L. *see* BOURGOIN, H.
GUNNELL, D. *see* HAWTON, K.
GUO, Y.J. *see* ZHANG, Y.F.
GUVEL, S. *see* ALTAN-YAYCIOGLU, R.

HALL, S.D. *see* PINTO, A.G.
HALLER, C.A. *see* CSAJKA, C.
HAMMAN, M. *see* PINTO, A.G.
HAQUE, N. *see* PAYNE, G.S.
HARADA, K.-I. *see* ARAKAWA, M.
HAUG-PIHALE, G. *see* SOBUE, S.
HAWLEY, C.M. *see* ATCHESON, B.A.
HAWTON, K., SIMKIN, S., GUNNELL, D., SUTTON, L., BENNEWITH, O., TURNBULL, P. & KAPUR, N. A multicentre study of coproxamol poisoning suicides based on coroners' records in England: 207
HEDNER, T. *see* LENNERNÄS, B.
HELMS, P. *see* NOVAK, P.H.
HELMS, P. *see* STEWART, D.
HELMS, P.J. *see* EKINS-DAUKES, S.
HELMS, P.J., DAUKES, S.E., TAYLOR, M.W., SIMPSON, C.R. & McLAY, J.S. Utility of routinely acquired primary care data for paediatric disease epidemiology and pharmacoepidemiology: 684
HEMPEL, G. Handbook of analytical separations, vol. 5: drug monitoring and clinical chemistry: 605

HERINGA, M. *see* CZOCK, D.
HERRMANN N. *see* JUURLINK, D.N.
HERTTUAINEN, J. *see* LÄHELMÄ, S.
HILL, A. *see* BOFFITO, M.
HINZ, B., CHEVTS, J., RENNER, B., WUTTKE, H., RAU, T., SCHMIDT, A., SZELENYI, I., BRUNE, K. & WERNER, U. Bioavailability of diclofenac potassium at low doses: 80
HO, D. *see* WALLER, P.
HOFFMANN, T.K. *see* BAS, M.
HOFMAN, A. *see* SCHELLEMAN, H.
HOFMANN, U. *see* NIEMI M.
HOLMBERG, M. *see* LENNERNÄS, B.
HOMBHANJE, F.W., HWAIHWANJE, I., TSUKAHARA, T., SARUWATARI, J., NAKAGAWA, M., OSAWA, H., PANIU, M.M., TAKAHASHI, N., LUM, J.K., AUMORA, B., MASTA, A., SAPURI, M., KOBAYAKAWA, T., KANEKO, A. & ISHIZAKI, T. The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria: 298
HORLANDER, J. *see* PINTO, A.G.
HOUGHTON, C.M. *see* BORRILL, Z.L.
HOUGHTON, C.M., WOODCOCK, A.A. & SINGH, D. A comparison of plethysmography, spirometry and oscillometry for assessing the pulmonary effects of inhaled ipratropium bromide in healthy subjects and patients with asthma: 152
HRUSKA, M.W., AMICO, J.A., LANGAEE, T.Y., FERRELL, R.E., FITZGERALD, S.M. & FRYE, R.F. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects: 70
HUGHES, D.M. *see* KERNOHAN, A.F.B.
HUI, C.K., CHEUNG, B.M.Y. & LAU, G.K.K. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis: 291
HUITEMA, A.D.R. *see* DE JONGE, M.E.
HUITEMA, A.D.R. *see* KAPPELHOFF, B.S.
HUONG, D.X. *see* GORDI, T.
HUONG, N.V. *see* GORDI, T.
HUSSEIN, Z., PITSIU, M., MAJID, O., AARONS, L., LONGUEVILLE, M.D. & STOCKIS, A. on behalf of the ETAC© Study Group Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC© study: 28
HWAIHWANJE, I. *see* HOMBHANJE, F.W.

IGARASHI, T. *see* SARASHINA, A.
IKEDA, H., MURAKAMI, T., TAKANO, M., USUI, T. & KIHIRA, K. Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient: 593
IMBIMBO, B.P. *see* ASTRUC, B.
ISBEL, N.M. *see* ATCHESON, B.A.
ISHIZAKI, T. *see* HOMBHANJE, F.W.

JACKSON, D. *see* STANLEY, A.G.
JANNUZZO, M.G. *see* VALLE, M.
JARRIN, I. *see* MAHÉ, I.
JIANG, X.M., WILLIAMS, K.M., LIAUW, W.S., AMMIT, A.J., ROUFOGALIS, B.D., DUKE, C.C., DAY, R.O. & MCLACHLAN, A.J. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects: 425
JOHNSON, D.W. *see* ATCHESON, B.A.
JOHNSON, T.N. Modelling approaches to dose estimation in children: 663
JULLIEN, V., TRÉLUYER, J.-M., CHAPPUY, H., DIMET, J., REY, E., DUPIN, N., SALMON, D., PONS, G. & URIEN, S. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients: 183
JUURLINK, D.N., MAMDANI, M.M., KOPP, A., HERRMANN N. & LAUPACIS, A. A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin: 102

KALMIJN, S. *see* VAN KAN, H.J.M.
KAM, P.C. *see* LADD, L.A.
KAM, P.C. *see* MCELDUFF, A.
KAMALI, F. *see* SCONCE, E.A.
KANEKO, A. *see* HOMBHANJE, F.W.
KAPPELHOFF, B.S., HUITEMA, A.D.R., CROMMENTUYN, K.M.L., MULDER, J.W., MEENHORST, P.L., VAN GORP, E.C.M., MAIRUHU, A.T.A. & BEIJNEN, J.H. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients: 174
KAPUR, N. *see* HAWTON, K.
KARLSSON, M.O. *see* GORDI, T.
KELA, M. *see* LÄHELMÄ, S.
KELLER, F. *see* CZOCK, D.
KERNOHAN, A.F.B., MCINTYRE, M., HUGHES, D.M., TAM, S.W., WORCEL, M. & REID, J.L. An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects: 85
KESSAR, P. *see* PAYNE, G.S.
KHAN, T.I. *see* SCONCE, E.A.
KHAZAAL, Y. *see* ZULLINO, D.F.
KIHIRA, K. *see* IKEDA, H.
KIM, K.-A. *see* SHON, J.-H.
KIM, M.-J. *see* SHON, J.-H.
KIRJAVAINEN, M. *see* LÄHELMÄ, S.
KIVISTÖ K.T. *see* NIEMI M.
KJELLBERG, L.M. *see* BOSCH, T.M.
KLONER, R.A. Heart disease and erectile dysfunction: 375
KLUNGEL, O.H. *see* SCHELLEMAN, H.
KLUVER, L. *see* GREEN, B.
KNIBBE, C.A.J., ZUIDEVELD, K.P., AARTS, L.P.H.J., KUKS, P.F.M. & DANHOF, M. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults: 705
KOBAYAKAWA, T. *see* HOMBHANJE, F.W.
KOJDA, G. *see* BAS, M.
KOLWANKAR, D. *see* PINTO, A.G.
KOPP, A. *see* JUURLINK, D.N.
KUBITZA, D. *see* STASS, H.
KUKS, P.F.M. *see* KNIBBE, C.A.J.

LÄHELMÄ, S., KIRJAVAINEN, M., KELA, M., HERTTUAINEN, J., VAHTERISTO, M., SILVASTI, M. & RANKI-PESONEN, M. Equivalent lung deposition of budesonide *in vivo*: a comparison of dry powder inhalers using a pharmacokinetic method: 167
LADD, L.A., KAM, P.C., WILLIAMS, D.B., WRIGHT, A.W.E., SMITH, M.T. & MATHER, L.E. Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions: 524
LADERO, J.M. *see* MARTÍNEZ, C.
LAFOREST, L. *see* VAN GANSE, E.
LALONDE, L. *see* PERREAULT, S.
LAMARRE, D. *see* PERREAULT, S.
LANGAEE, T.Y. *see* HRUSKA, M.W.
LAU, G.K.K. *see* HUI, C.K.
LAUPACIS, A. *see* JUURLINK, D.N.
LAURIER, C. *see* PERREAULT, S.
LAVORINI F. Quantifying bronchodilator responses in chronic obstructive pulmonary disease trials: 385
LE JEUNNE, P. *see* VAN GANSE, E.
LEACH, M.O. *see* PAYNE, G.S.
LEBRANCHU, Y. *see* BOURGOIN, H.
LECHEVALLIER-MICHEL, N., MOLIMARD, M., DARTIGUES, J.-F., FABRIGOULE, C. & FOURRIER-RÉGLAT, A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study: 143
LEE, A. *see* ZHOU, Q.Y.
LEE, C.H. *see* SHON, J.-H.
LEE, E.J.D. *see* ZHOU, Q.Y.
LENNERNÄS, B., HEDNER, T., HOLMBERG, M., BREDENBERG, S., NYSTRÖM, C. & LENNERNÄS, H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly

dissolving tablet to cancer patients: a new approach to treatment of incident pain: 249
LENNERNÄS, H. *see* LENNERNÄS, B.
LESLIE, S.J. *see* GREIG, L.D.
LEWITH, G. *see* STEINSBEKK, A.
LIAUW, W.S. *see* JIANG, X.M.
LILJA, J.J., BACKMAN, J.T. & NEUVONEN, P.J. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects: 433
LIM, Y.-C. *see* SHON, J.-H.
LINGVALL, M., REITH, D. & BROADBENT, R. The effect of sepsis upon gentamicin pharmacokinetics in neonates: 54
LIPWORTH, B.J., SIMS, E.J. TAYLOR, K., COCKBURN, W. & FISHMAN, R. Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose© Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin™ Evohaler™) in moderate to severe asthmatics: 5
LIU, K.-H. *see* SHON, J.-H.
LOBOZ, K.K. & SHENFIELD, G.M. Drug combinations and impaired renal function – the 'triple whammy': 239
LONGUEVILLE, M.D. *see* HUSSEIN, Z.
LOYNDS, P. *see* PAYNE, G.S.
LUM, J.K. *see* HOMBHANJE, F.W.

MACKSON, J.M. *see* WEEKES, L.M.
MAHÉ, I., BERTRAND, N., DROUET, L., SIMONEAU, G., MAZOYER, E., BAL DIT SOLLIER, C., CAULIN, C. & BERGMANN, J.F. Paracetamol: a haemorrhagic risk factor in patients on warfarin: 371
MAHÉ, I., MOULY, S., JARRIN, I., OTÉRO, J., TAVERA, C., SIMONEAU, G., TILLET, Y., CONTI, R., MESKI, S.E., GAUDRIC, A. & BERGMANN, J.-F. Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose-ranging, double-blind, randomized trial in healthy volunteers: 220
MAIRUHU, A.T.A. *see* KAPPELHOFF, B.S.
MAJID, O. *see* HUSSEIN, Z.
MALHOTRA, S. *see* SHAFIQ, N.
MALIK, M. *see* CHAIKIN, P.
MAMDANI, M.M. *see* JUURLINK, D.N.
MARIOTTI, F. *see* ASTRUC, B.
MARTÍNEZ, C., GARCÍA-MARTÍN, E., BLANCO, G., GAMITO, F.J.G., LADERO, J.M. & AGÚNDEZ, J.A.G. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects: 62
MARTÍNEZ, C., GARCÍA-MARTÍN, E., BLANCO, G., GAMITO, F.J.G., LADERO, J.M. & AGÚNDEZ, J.A.G. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects: 69
MARTINI, N. *see* MOTOLA, D.
MASON, J. *see* SCONCE, E.A.
MASTA, A. *see* HOMBHANJE, F.W.
MATHER, L.E. *see* LADD, L.A.
MATHER, L.E. *see* MCELDUFF, A.
MAZOYER, E. *see* MAHÉ, I.
McCAIG, D. *see* STEWART, D.
MCELDUFF, A., MATHER, L.E., KAM, P.C. & CLAUSON, P. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx© insulin Diabetes Management System: 546
MCINTYRE, M. *see* KERNOHAN, A.F.B.
MCLACHLAN, A.J. *see* JIANG, X.M.
McLAY, J. *see* STEWART, D.
McLAY, J.S. *see* EKINS-DAUKES, S.
McLAY, J.S. *see* HELMS, P.J.
McLAY, J.S. *see* NOVAK, P.H.
MEENHORST, P.L. *see* KAPPELHOFF, B.S.
MEIJERMAN, I. *see* BOSCH, T.M.
MENTRÉ, F. *see* BOURGOIN, H.
MESKI, S.E. *see* MAHÉ, I.
MILNE, R.M. *see* NOVAK, P.H.
MITCHELL, A. *see* SAEZ, A.M.O.
MÖLLER, J.-G. *see* STASS, H.
MOLIMARD, M. *see* LECHEVALLIER-MICHEL, N.
MONTANARO, N. *see* MOTOLA, D.
MONTGOMERY, K. *see* NATH, C.E.
MORGAN, P. *see* OWEN, A.
MORRIS, A. *see* DAVIES, J.
MOSEL, F. *see* SAEZ, A.M.O.
MOTOLA, D., DE PONTI, F., ROSSI, P., MARTINI, N. & MONTANARO, N. Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003: 475
MOULD, G. *see* PAYNE, G.S.
MOULIN, P. *see* VAN GANSE, E.
MOULY, S. *see* MAHÉ, I.
MOYLE, G. *see* BOFFITO, M.
MUDGE, D.W. *see* ATCHESON, B.A.
MULDER, J.W. *see* KAPPELHOFF, B.S.
MUNAKATA, A. *see* SAITO, M.
MURAKAMI, T. *see* IKEDA, H.
MURPHY, P.S. *see* PAYNE, G.S.
MURRAY, M.L. *see* WONG, I.C.K.

NAKAGAWA, M. *see* HOMBHANJE, F.W.
NATH, C.E., SHAW, P.J., MONTGOMERY, K. & EARL, J.W. Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation: 314
NELSON, M. *see* BOFFITO, M.
NEUVONEN, P.J. *see* LILJA, J.J.
NEWBY, D.E. *see* GREIG, L.D.
NIEMI, M., KIVISTÖ, K.T., HOFMANN, U., SCHWAB, M., EICHELBAUM, M. & FROMM, M.F. Fexofenadine pharmacokinetics are associated with a polymorphism of the *SLCO1B1* gene (encoding OATP1B1): 602
NOBLE, F. *see* SCONCE, E.A.
NORRIS, P. *see* GRIEVE, J.
NOVAK, P.H., EKINS-DAUKES, S., SIMPSON, C.R., MILNE, R.M., HELMS, P. & McLAY, J.S. Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care: 712
NÜRNBERGER, J. *see* SAEZ, A.M.O.
NUNN, T. & WILLIAMS, J. Formulation of medicines for children: 674
NYSTRÖM, C. *see* LENNERNÄS, B.

OHMORI, M. *see* ARAKAWA, M.
OSAWA, H. *see* HOMBHANJE, F.W.
OTÉRO, J. *see* MAHÉ, I.
OWEN, A., GOLDRING, C., MORGAN, P., CHADWICK, D., PARK, B.K. & PIRMOHAMED, M. Relationship between the $C_{3435}T$ and $G_{2677}T(A)$ polymorphisms in the *ABCB1* gene and P-glycoprotein expression in human liver: 365
OZKARDES, H. *see* ALTAN-YAYCIOGLU, R.

PAINTAUD, G. *see* BOURGOIN, H.
PANDHI, P. *see* SHAFIQ, N.
PANIU, M.M. *see* HOMBHANJE, F.W.
PARK, B.K. *see* OWEN, A.
PAYNE, G.S., COLLINS, D.J., LOYNDS, P., MOULD, G., MURPHY, P.S., DZIK-JURASZ, A.S.K., KESSAR, P., HAQUE, N., YAMAGUCHI, M., ATARASHI, S. & LEACH, M.O. Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using *in vivo* ^{19}F magnetic resonance spectroscopy: 244
PENTIKIS, H. *see* CHAIKIN, P.
PERREAULT, S., BLAIS, L., LAMARRE, D., DRAGOMIR, A., BERBICHE, D., LALONDE, L., LAURIER, C., ST-MAURICE, F. & COLLIN, J. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention: 564
PERRI, G.D. *see* BOFFITO, M.
PHILIPP, T. *see* SAEZ, A.M.O.
PHILLIPS, S.R. *see* WEEKES, L.M.
PILLANS, P.I. *see* ATCHESON, B.A.
PILLININI, P.P. *see* COPETTI, R.
PINTO, A.G., HORLANDER, J., CHALASANI, N., HAMMAN, M.,

ASGHAR, A., KOLWANKAR, D. & HALL, S.D. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity *in vivo* without altering the expression of intestinal mRNA or protein: 440
PIRMOHAMED, M. *see* OWEN, A.
PITSIU, M. *see* HUSSEIN, Z.
POGGESI, I. *see* VALLE, M.
PONS, G. *see* JULLIEN, V.
POON, D. *see* ZHOU, Q.Y.
POZNIAK, A. *see* BOFFITO, M.
PRITCHARD, D.S., BABER, N. & STEPHENSON, T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old: 725
PROCLEMER, A. *see* COPETTI, R.
PURDIE, D.M. *see* SORENSEN, L.

RANKI-PESONEN, M. *see* LÄHELMÄ, S.
RASCHE, F.M. *see* CZOCK, D.
RAU, T. *see* HINZ, B.
REID, J.L. *see* KERNOHAN, A.F.B.
REIDENBERG, M.M. Statins, lack of energy and ubiquinone: 606
REITH, D. *see* CHUI, J.
REITH, D. *see* GRIEVE, J.
REITH, D. *see* LINGVALL, M.
RENNER, B. *see* HINZ, B.
REY, E. *see* JULLIEN, V.
RHODES, G.R. *see* CHAIKIN, P.
ROBERTS, D.J. *see* CHAIKIN, P.
ROBERTS, M.S. *see* SORENSEN, L.
ROBSON, R. *see* SNELL, P.
ROCCHETTI, M. *see* VALLE, M.
RODENHUIS, S. *see* DE JONGE, M.E.
ROSE, K. Better medicines for children – where are we now, and where do we want to be?: 657
ROSSI, P. *see* MOTOLA, D.
ROUFOGALIS, B.D. *see* JIANG, X.M.
ROWELL, J. *see* GREEN, B.
ROWELL, L. *see* SNELL, P.
RUSHENTSOVA, U. *see* SAEZ, A.M.O.

SAEZ, A.M.O., MOSEL, F., NÜRNBERGER, J., RUSHENTSOVA, U., GÖSSL, M., MITCHELL, A., SCHÄFERS, R.F., PHILIPP, T. & WENZEL, R.R. Laser Doppler imager (LDI) scanner and intradermal injection for *in vivo* pharmacology in human skin microcirculation: responses to acetylcholine, endothelin-1 and their repeatability: 511
SAITO, M., YASUI-FURUKORI, N., UNO, T., TAKAHATA, T., SUGAWARA, K., MUNAKATA, A. & TATEISHI, T. Effects of clarithromycin on lansoprazole pharmacokinetics between *CYP2C19* genotypes: 302
SAITOH, T. *see* ARAKAWA, M.
SAKAMOTO, K. *see* WAKAUMI, M.
SALEK, M.S. *see* AL-MOTARREB, A.
SALLE, E.D. *see* VALLE, M.
SALMON, D. *see* JULLIEN, V.
SALTISSI, D. *see* GREEN, B.
SAPURI, M. *see* HOMBHANJE, F.W.
SARASHINA, A., TATAMI, S., YAMAMURA, N., TSUDA, Y. & IGARASHI, T. Population pharmacokinetics of epinastine, a histamine H_1 receptor antagonist, in adults and children: 43
SARUWATARI, J. *see* HOMBHANJE, F.W.
SCHÄFERS, R.F. *see* SAEZ, A.M.O.
SCHELLEMAN, H., KLUNGEL, O.H., VAN DUIJN, C.M., WITTEMAN, J.C.M., HOFMAN, A., DE BOER, A. & CH STRICKER, B.H. Insertion/deletion polymorphism of the *ACE* gene and adherence to ACE inhibitors: 483
SCHELLENS J.H.M. *see* BOSCH, T.M.
SCHELLENS, J.H.M. *see* DE JONGE, M.E.
SCHMIDT, A. *see* HINZ, B.
SCHWAB, M. *see* NIEMI M.
SCONCE, E.A., MASON, J., NOBLE, F., KHAN, T.I., WYNNE, H.A. & KAMALI, F. Patients with unstable control have a poorer dietary intake of vitamin K compared with patients with stable control of anticoagulation: 624
SEGUIN, I. *see* VAN HEESWIJK, R.P.G.
SHAFIQ, N., MALHOTRA, S., PANDHI, P., GROVER, A. & UBOWEJA, A. A meta-analysis of clinical trials of paclitaxel- and sirolimus-eluting stents in patients with obstructive coronary artery disease: 94
SHAKIR, S. *see* WALLER, P.
SHAW, M. *see* WALLER, P.
SHAW, P.J. *see* NATH, C.E.
SHENFIELD, G.M. *see* COCKAYNE, N.L.
SHENFIELD, G.M. *see* LOBOZ, K.K.
SHIGA, T. *see* WAKAUMI, M.
SHIN, D.-H. *see* SHON, J.-H.
SHIN, J.-G. *see* SHON, J.-H.
SHON, J.-H., YOON, Y.-R., KIM, M.-J., KIM, K.-A., LIM, Y.-C., LIU, K.-H., SHIN, D.-H., LEE, C.H., CHA, I.-J. & SHIN, J.-G. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 *in vitro*: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism: 552
SI, D.Y. *see* ZHANG, Y.F.
SILVASTI, M. *see* LÄHELMÄ, S.
SIMKIN, S. *see* HAWTON, K.
SIMONEAU, G. *see* MAHÉ, I.
SIMPSON, C.R. *see* EKINS-DAUKES, S.
SIMPSON, C.R. *see* HELMS, P.J.
SIMPSON, C.R. *see* NOVAK, P.H.
SIMS, E.J. *see* LIPWORTH, B.J.
SINGH, D. *see* BORRILL, Z.L.
SINGH, D. *see* HOUGHTON, C.M.
SMITH, M.T. & DE LA IGLESIA, F.A. Co-administration of oxycodone and morphine and analgesic synergy re-examined: 486
SMITH, M.T. *see* LADD, L.A.
SMITS, P.H.M. *see* BOSCH, T.M.
SMYTH, R. *see* BABER, N.S.
SNELL, P., DAVE, N., WILSON, K., ROWELL, L., WEIL, A., GALITZ, L. & ROBSON, R. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate: 598
SOBUE, S., TAN, K. & HAUG-PIHALE, G. The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole: 160
SORENSEN, L., STOKES, J.A., PURDIE, D.M., WOODWARD, M., ELLIOT, R. & ROBERTS, M.S. Medication reviews in the community: results of a randomized, controlled effectiveness trial: 376
SOUCHET, T. *see* VAN GANSE, E.
SPARREBOOM, A. *see* ZHOU, Q.Y.
SPIEKSMA, M. *see* VAN KAN, H.J.M.
SPINELLI, R. *see* VALLE, M.
STAINSBY-TRON, M. *see* BOFFITO, M.
STANLEY, A.G., JACKSON, D. & BARNETT, D.B. The teaching of drug development to medical students: collaboration between the pharmaceutical industry and medical school: 464
STASS, H., KUBITZA, D., MÖLLER, J.-G. & DELESEN, H. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400mg single dose to healthy males: 536
STEINSBEKK, A. BENTZEN, N., FØNNEBØ, V. & LEWITH, G. Self treatment with one of three self selected, ultramolecular homeopathic medicines for the prevention of upper respiratory tract infections in children. A double-blind randomized placebo controlled trial: 447
STEPHENSON, T. How children's responses to drugs differ from adults: 670
STEPHENSON, T. *see* PRITCHARD, D.S.
STEWART, D., HELMS, P., McCAIG, D., BOND, C. & McLAY, J. Monitoring adverse drug reactions in children using community pharmacies: a pilot study: 677
ST-MAURICE, F. *see* PERREAULT, S.
STOCKIS, A. *see* HUSSEIN, Z.
STOKES, J.A. *see* SORENSEN, L.
STRUTHERS, A. *see* DAVIES, J.
SUGAWARA, K. *see* SAITO, M.

SUTTON, L. *see* HAWTON, K.
SZELENYI, I. *see* HINZ, B.

TAKAHASHI, N. *see* HOMBHANJE, F.W.
TAKAHATA, T. *see* SAITO, M.
TAKANO, M. *see* IKEDA, H.
TAM, S.W. *see* KERNOHAN, A.F.B.
TAN, E.-H. *see* ZHOU, Q.Y.
TAN, K. *see* SOBUE, S.
TAN, S. *see* GREIG, L.D.
TARRAL, A. *see* ASTRUC, B.
TATAMI, S. *see* SARASHINA, A.
TATEISHI, T. *see* SAITO, M.
TAVERA, C. *see* MAHÉ, I.
TAYLOR, K. *see* LIPWORTH, B.J.
TAYLOR, M.W. *see* EKINS-DAUKES, S.
TAYLOR, M.W. *see* HELMS, P.J.
TAYLOR, P.J. *see* ATCHESON, B.A.
TEELING, M., BENNETT, K. & FEELY, J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998–2002: 227
TETT, S.E. *see* ATCHESON, B.A.
TILLET, Y. *see* MAHÉ, I.
TITCHEN, T., CRANSWICK, N. & BEGGS, S. Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital: 718
TOMKINS, J. *see* BOFFITO, M.
TORDOFF, J. *see* CHUI, J.
TORDOFF, J. *see* GRIEVE, J.
TRAVIER, N. *see* VAN GANSE, E.
TRÉLUYER, J.-M. *see* JULLIEN, V.
TSUDA, Y. *see* SARASHINA, A.
TSUKAHARA, T. *see* HOMBHANJE, F.W.
TSUR, S.A. Elsevier's dictionary of abbreviations, acronyms, synonyms and symbols used in medicine, 2nd enlarged edition: 117
TSURUOKA S. *see* WAKAUMI, M.
TURNBULL, P. *see* HAWTON, K.

UBOWEJA, A. *see* SHAFIQ, N.
UNO, T. *see* SAITO, M.
URIEN, S. *see* JULLIEN, V.
USUI, T. *see* IKEDA, H.

VAHTERISTO, M. *see* LÄHELMÄ, S.
VALLE, M., SALLE, E.D., JANNUZZO, M.G., POGGESI, I., ROCCHETTI, M., SPINELLI, R. & VEROTTA, D. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation: 355
VAN DEN BERG, L.H. *see* VAN KAN, H.J.M.
VAN DUIJN, C.M. *see* SCHELLEMAN, H.
VAN GANSE, E., SOUCHET, T., LAFOREST, L., MOULIN, P., BERTRAND, M., LE JEUNNE, P., TRAVIER, N., YIN, D., ALEMAO, E. & DE POUVOURVILLE, G. Ineffectiveness of lipid-lowering therapy in primary care: 456
VAN GERVEN, J.M.A. *see* DUMONT, G.J.H.
VAN GORP, E.C.M. *see* KAPPELHOFF, B.S.
VAN HEESWIJK, R.P.G., BOURBEAU, M., SEGUIN, I., GIGUERE, P., GARBER, G.E. & CAMERON, D.W. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients: 398
VAN KAN, H.J.M., GROENEVELD, G.J., KALMIJN, S., SPIEKSMA, M., VAN DEN BERG, L.H. & GUCHELAAR, H.J. Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis: 310
VAN OVERMEIRE, B. *see* ALLEGAERT, K.
VANMOLKOT, F.H.M. & DE HOON, J.N.J.M. Reproducibility of forearm vasodilator response to intra-arterial infusion of calcitonin gene-related peptide assessed by venous occlusion plethysmography: 387
VEROTTA, D. *see* CSAJKA, C.
VEROTTA, D. *see* VALLE, M.
VESTBO, J. *see* BORRILL, Z.L.

WAKAUMI, M., TSURUOKA S., SAKAMOTO, K., SHIGA, T. & FUJIMURA, A. Pilsicainide in breast milk from a mother: comparison with disopyramide and propafenone: 120
WALLER, P., SHAW, M., HO, D., SHAKIR, S. & EBRAHIM, S. Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database: 213
WARREN, J. Obesity: weighing the risk before prescribing: 259
WEBB, D.J. *see* GREIG, L.D.
WEEKES, L.M., MACKSON, J.M., FITZGERALD, M. & PHILLIPS, S.R. National Prescribing Service: creating an implementation arm for national medicines policy: 112
WEIL, A. *see* SNELL, P.
WENZEL, R.R. *see* SAEZ, A.M.O.
WERNER, U. *see* HINZ, B.
WESTHUYZEN, J. *see* GREEN, B.
WILLIAMS, D.B. *see* LADD, L.A.
WILLIAMS, J. *see* NUNN, T.
WILLIAMS, K.M. *see* JIANG, X.M.
WILSON, K. *see* SNELL, P.
WITTEMAN, J.C.M. *see* SCHELLEMAN, H.
WONG, I.C.K. & MURRAY, M.L. The potential of UK clinical databases in enhancing paediatric medication research: 750
WONG, R.S.M. *see* YOU, J.H.S.
WOODCOCK, A.A. *see* BORRILL, Z.L.
WOODCOCK, A.A. *see* HOUGHTON, C.M.
WOODWARD, M. *see* SORENSEN, L.
WORCEL, M. *see* KERNOHAN, A.F.B.
WRIGHT, A.W.E. *see* LADD, L.A.
WUTTKE, H. *see* HINZ, B.
WYNNE, H.A. *see* SCONCE, E.A.

XIE, R. *see* GORDI, T.

YAMAGUCHI, M. *see* PAYNE, G.S.
YAMAMURA, N. *see* SARASHINA, A.
YASUI-FURUKORI, N. *see* SAITO, M.
YAYCIOGLU, O. *see* ALTAN-YAYCIOGLU, R.
YIN, D. *see* VAN GANSE, E.
YOON, Y.-R. *see* SHON, J.-H.
YOU, J.H.S., CHAN, F.W.H., WONG, R.S.M. & CHENG, G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?: 582

ZHANG, Y.F., ZHONG, D.F., SI, D.Y., GUO, Y.J., CHEN, X.Y. & ZHOU, H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype: 14
ZHONG, D.F. *see* ZHANG, Y.F.
ZHOU, H. *see* ZHANG, Y.F.
ZHOU, Q.Y., SPARREBOOM, A., TAN, E.-H., CHEUNG, Y.-B., LEE, A., POON, D., LEE, E.J.D. & CHOWBAY, B. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer: 415
ZUIDEVELD, K.P. *see* KNIBBE, C.A.J.
ZULLINO, D.F. & KHAZAAL, Y. Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions: 118

DOI:10.1111/j.1365-2125.2005.02459.x

SUBJECT INDEX

This index was compiled from the keywords

^{19}F MRS, 244
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, 291

A, 365
abacavir, 183
ABC transporters, 415
ABCB1, 365
accommodation, 588
ACE gene, 483
ACE inhibitors, 239, 483
acetylcholine, 511
activated charcoal, 536
acute coprescribing, 712
acute-phase-proteins, 233
adult(s), 43, 183
adverse drug reaction(s), 108, 213, 677, 718
AERx® iDMS, 546
aged, 143
allometric scaling, 705
amodiaquine, 298
amyl nitrite, 265
anaesthesia, 220
angioedema, 233
angiotensin converting enzyme inhibitor, 233
anticancer agents, 593
anticholinergic drugs, 143
anticoagulant(s), 371, 425
antidepressants, 102
antihistamine, 28
antimicrobials, 244
antiretroviral drugs, 38
antoinduction, 189
apgar, 54
artemisinin, 189
asthma, 5, 152
attitude, 743

Bayesian estimation, 18
bioavailability, 80, 542
Biomarker, 495
biotechnological drugs, 475
bleeding, 371
body composition, 691
bodyweight, 183
Bronchodilation, 379
budesonide, 167
bupivacaine, 220

C3435T, 365
caffeine, 335
Calcarea carb, 447
calcitonin gene-related peptide, 387
carboplatin, 314
case-control study, 574
cetirizine, 28
chemotherapy, 593
CHF3381, 405
child, 43, 674, 712, 730, 743
children, 314, 447, 677, 684, 691, 705
Chinese patients, 582
chlorpropamide, 552
circadian, 398
cirrhosis, 291
cisplatin, 593
clarithromycin, 302
clinical databases, 750
clinical pharmacokinetics, 14
clinical pharmacology and therapeutics, 464
clinical practice, 227
clinical trials, 379
cognition, 143
community, 677
complementary and alternative medicines, 254
COPD, 379
coproxamol, 207
coronary artery disease, 94
coronary heart disease, 456
coroners, 207
C-reactive protein, 233
creatinine clearance, 239
cremophor EL, 325
cyclooxygenase 2 inhibitors, 718
cyclosporin, 18
CYP1A2, 310
CYP2C8, 70, 62, 298
CYP2C9, 62, 433, 552
CYP2C9 polymorphism, 14
CYP2C19, 302, 552
CYP3A, 302, 440
cytochrome P450, 2C, 199
cytochrome P450, 3A4, 199

desethylamodiaquine, 298
determinants, 564
diabetes, 520, 546
diclofenac, 80
digoxin, 102
diltiazem, 440
diuretics, 239
domperidone, 725
dosage form, 674
drug development, 464
drug evaluation, 475
drug interaction(s), 38, 70, 102, 254
drug metabolizing enzymes, 415
drug safety, 213
drug utilization, 750
drug–drug interaction, 433, 712
dry eye, 588
dry powder inhaler, 167
dyslipidaemia, 456

ebastine, 346
effectiveness, 456
endothelial function, 265
endothelin-1, 511
enoxaparin, 281
enterocytes, 199
enterohepatic recycling, 479
ephedra alcaloids, 335
epidemiology, 108
epilepsy, 712
epileptic patient, 593
epinastine, 43
ETAC, 28
European centralised procedure, 475
exemestane, 355
expression, 365

fentanyl, 249
forearm blood flow, 387
Formulation, 674
fosfluconazole, 160
free drug, 271

G2677T, 365
gastro-oesophageal reflux, 725
gastro-oesophageal reflux disease, 725
gemfibrozil, 433
genotype, 62
gentamicin, 54, 542
ginger, 425
ginkgo, 425
glucuronide, 271
GTN, 265
guidelines, 227

hepatic impairment, 160, 598
herb–drug interactions, 425
HES data, 213
HIV, 183, 398
homeopathy, 447
homoeopathy, 743
hospital admission, 213
human small intestine, 199
hyaluronic acid, 220
hypertension, 520

in vitro, 552
in vivo, 552
incident pain, 249
infants, 691
influenza, 598
inhalation devices, 5
inhalation, 542

© 2005 Blackwell Publishing Ltd

inhaled insulin, 546
INR, 371
interaction, 335, 371
international comparisons, 108
intestinal biopsy, 440
intraocular pressure, 588
ipratropium, 152
irreversible inhibition, 440

ketoconazole, 346
khat, 574
kidney failure, 281

lansoprazole, 302
L-arginine, 85
Laser Doppler imager, 511
levocetirizine, 28
lipid-lowering agents, 456
liver, 291
lopinavir, 398
loratadine, 346
lornoxicam, 14
lung deposition, 167
lungs, 542

male erectile dysfunction, 85
MAO-A inhibitors, 405
MDR1, 365
medical education, 464
medical history taking, 254
medicines for children, 657
medicines policy, 112
medicines, 684, 736
Melphalan pharmacokinetics, 314
meta-analysis, 94
metabolism, 310
microvascular, 511
midazolam, 440, 691
model, 355
modelling, 281
moxifloxacin, 536
mycophenolic acid, 271
myocardial infarction, 574

nebulizer, 542
neonate, 54
nested case–control studies, 102
neuromuscular disease, 310
neuropathic pain, 405
nitric oxide, 85
nitroglycerine, 85
NMDA antagonists, 405
NMI, 861, 85
NONMEM, 281, 355
nonsteroidal anti-inflammatory drugs, 239
NSAID, 718

oesophagitis, 725
off label, 736
off label prescribing, 712
off-label, 730
opioid effect, 524
opthalmic insert, 220
optimal INR, 582
oral administration, 325
oscillometry, 152
oseltamivir carboxylate, 598
oseltamivir, 598
overactive bladder, 588
oxybutynin, 588

paclitaxel, 94, 325
paediatric(s), 674, 718, 736, 750
paediatric dosage, 43
paediatric population pharmacokinetics, 28
paracetamol, 371, 718
parental, 677
pediatric drug development, 657
Pediatric Exclusivity, 730
persistence, 564
P-glycoprotein, 102, 365
pharmaceutical industry, 464
pharmacodynamic, 355
pharmacodynamics, 346, 546
pharmacoeconomics, 108
pharmacoepidemiology, 102, 143
pharmacokinetic, 355
pharmacokinetic interaction, 593
pharmacokinetic model, 189
pharmacokinetics, 54, 80, 160, 167, 174, 244, 249, 271, 281, 291, 310, 335, 346, 398, 479, 536, 546, 598, 691, 705
pharmacovigilance, 213, 750
pharmacy, 677
phase I, 495
phenotype, 62
pitavastatin, 291
poisoning, 207
polymorphism, 483
population, 355
population pharmacokinetics, 18, 43, 183, 325
potassium salt, 80
prescribing disease epidemiology, 684
prescribing trends, 227
prevention, 447
primary care, 684
primary health care, 712, 743
primary prevention, 564
propofol, 705
protein binding, 271
Pulsatilla, 447

QTc interval, 346
questionnaire, 677

raloxifene, 479
randomized controlled trial, 447
randomized trial, 220
rational drug use, 112
registration, 730
regurgitation, 725
renal failure, 239
renal function, 314
renal impairment, 479
renal transplant recipients, 18
renal transplantation, 271
reproducibility, 387
rifampicin, 199
riluzole, 310
ritonavir, 38, 174, 398
rosiglitazone, 70

salbutamol, 5
saquinavir, 38
scientometrics, 108
secondary prevention, 564
self treatment, 447
sepsis, 54
sildenafil, 85
single nucleotide polymorphisms, 415
sirolimus, 94
sitafloxacin, 244
smoking, 574
SNP, 365
spironolactone, 520
SSRIs, 495
statin, 291, 227, 564
stents, 94
stimulated hypercapnic response, 524
sublingual administration, 249
suicide, 207
sulphur, 447

tenofovir, 38
theophylline, 691
theraputic innovation, 475
tissue distribution, 691
tolterodine, 588
topicsert, 220
trimethoprim, 70

UK, 750
unlicensed, 730, 736
upper respiratory tract infection, 447, 546

valproic acid, 593
vasodilation, 387
venous occlusion plethysmography, 387
ventilatory depression, 524

warfarin, 371, 425, 433, 582
weight, 314

yohimbine, 85